By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Data detailed on Diabetes have been presented. According to news reporting out of Antalya, Turkey, by NewsRx editors, research stated, "Glucagon-like peptide (GLP)-1 is an incretin hormone with several antidiabetic functions including stimulation of glucose-dependent insulin secretion, increase in insulin gene expression and beta-cell survival. Despite the initial technical difficulties and profound inefficiency of direct gene transfer into the pancreas that seriously restricted in vivo gene transfer experiments with GLP-1, recent exploitation of various routes of gene delivery and alternative means of gene transfer has permitted the detailed assessment of the therapeutic efficacy of GLP-1 in animal models of type 2 diabetes (T2DM)."
Our news journalists obtained a quote from the research from the University of Akdeniz, "As a result, many clinical benefits of GLP-1 peptide/analogues observed in clinical trials involving induction of glucose tolerance, reduction of hyperglycaemia, suppression of appetite and food intake linked to weight loss have been replicated in animal models using gene therapy. Furthermore, GLP-1-centered gene therapy not only improved insulin sensitivity, but also reduced abdominal and/or hepatic fat associated with obesity-induced T2DM with drastic alterations in adipokine profiles in treated subjects."
According to the news editors, the research concluded: "Thus, a comprehensive assessment of recent GLP-1-mediated gene therapy approaches with detailed analysis of current hurdles and resolutions, is discussed."
For more information on this research see: GLP-1-mediated gene therapy approaches for diabetes treatment. Expert Reviews In Molecular Medicine, 2014;16():e7. Expert Reviews In Molecular Medicine can be contacted at: Cambridge University Press, 32 Avenue of the Americas, New York, NY 10013-2473. (Cambridge University Press - www.cambridge.org; Expert Reviews In Molecular Medicine - journals.cambridge.org/action/displayJournal?jid=ERM)
Our news journalists report that additional information may be obtained by contacting M.H. Tasyurek, Human Gene and Cell Therapy Center, Akdeniz University Hospitals, Antalya 07058, Turkey. Additional authors for this research include H.A. Altunbas, H. Canatan, T.S. Griffith and S. Sanlioglu (see also Diabetes).
Publisher contact information for the journal Expert Reviews In Molecular Medicine is: Cambridge University Press, 32 Avenue of the Americas, New York, NY 10013-2473.
Keywords for this news article include: Biotechnology, Turkey, Antalya, Eurasia, Diabetes, Proinsulin, Gene Therapy, Bioengineering, Peptide Hormones, Clinical Trials and Studies.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC